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The important role of cyclooxygenase-2 (COX-2) in the pathogenesis of inflammation and side effect
limitations of current COX-2 inhibitor drugs illustrates a need for the design of new compounds based on
alternative structural templates. We previously reported a set of substituted 1,5-diarylpyrrole derivatives,
along with their inhibitory activity toward COX enzymes. Several compounds proved to be highly selective
COX-2 inhibitors and their affinity data were rationalized through docking simulations. In this paper, we
describe the synthesis of new 1,5-diarylpyrrole derivatives that were assayed for their in vitro inhibitory
effects toward COX isozymes. Among them, the ethyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1-[3-
fluorophenyl]-1H-pyrrol-3-acetate (1d), which was the most potent and COX-2 selective compound, also
showed a very interesting in vivo anti-inflammatory and analgesic activity, laying the foundations for
developing new lead compounds that could be effective agents in the armamentarium for the management
of inflammation and pain.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) represent the
standard therapy for the management of inflammation and pain.
Although all available NSAIDs are ineffective against disease
progression, they show similar antipyretic, anti-inflammatory,
and analgesic effects and prove, in particular, to be useful in
the treatment of rheumatoid arthritis and osteoarthritis.1 NSAIDs
indiscriminately inhibit both isoforms of cyclooxygenases
(COX; constitutive COX-1, responsible for cytoprotective effects
and inducible COX-2, responsible for inflammatory effects) with
the consequence that they are usually associated with well-
known side effects at the gastrointestinal level (mucosal damage,
bleeding) and, less frequently, at the renal level.2 Recent studies
have shown that selective COX-2 inhibitors are devoid of the
undesirable effects associated with classical, nonselective
NSAIDs,3 and they can also induce apoptosis in colon, stomach,
prostate, and breast cancer cell lines.4 Among them, celecoxib
(3, Chart 1),5 rofecoxib (4),6 valdecoxib (5),7 and etoricoxib
(6)8,9 have been clinically validated as anti-inflammatory
therapeutics for indications such as rheumatoid arthritis. Most
of them are characterized by a 1,2-diaryl substitution on a central
heterocyclic or carbocyclic ring system. Structure-activity
relationship (SAR) studies have shown that a SO2Me or SO2-
NH2 substituent at the para position of one of the aryl rings
often provides optimum COX-2 selectivity and inhibitory
potency.10 Unfortunately, these compounds are associated with
well-known adverse cardiovascular effects, such as myocardial
infarction.11-13 The most plausible explanation for this effect
is the suppression of COX-2-dependent prostacyclin, which
constrains endogenous mediators of platelet activation, hyper-
tension, atherogenesis, and cardiac dysfunction.14 Moreover, it
must be considered that a clinical or genetic predisposition to
thrombosis would favor the emergence of a drug-related
cardiovascular event.15 The general impression, as suggested
by Fries,16 is that the efficacy and safety of these drugs is related
to multiple factors, such as the chemical properties of the drug
(i.e., the selectivity toward COX-2) and individual factors that
modulate drug response.16 Marked intersubject variability in the
response (both therapeutic and unwanted) to NSAIDs selective
for COX-2 and traditional NSAIDs illustrates a need for the
development of novel COX inhibitors that provide an appropri-
ate treatment option for each individual patient.
In this context, we recently reported several investigations
describing the design, synthesis, and anti-inflammatory proper-
ties of a class of novel pyrrole-containing anti-inflammatory
agents. We focused our attention on the synthesis of 1,5-
diarylpyrrol-3-acetic and -glyoxylic acid and esters (7, Chart
1) as new COX-2 selective inhibitors in which the pyrroleacetic
and vicinal diaryl heterocyclic moieties17 were reminiscent both
of indomethacin (8) and of the above-cited “coxib” family,
respectively. Biological evaluation of compounds 7 showed that
insertion of the acetic moiety in the coxib-like scaffold gives
rise to very potent and selective COX-2 inhibitors. Among them,
several 3-pyrroleacetic esters had very interesting biological
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activity profiles, and, in particular, the hit compound (7a, Chart
1) exhibited excellent in vitro inhibitory potency toward COX-
2, being more active and selective than celecoxib. Such
compounds were submitted to a two-step computational protocol
consisting of molecular docking calculations and structural
optimization of the corresponding complexes. Results led us to
hypothesize a binding mode for the pyrrole derivatives able to
account for their major SARs. Moreover, theoretical simulations
suggested structural modifications of the studied compounds
to obtain new derivatives with higher affinity toward COX-2.
Accordingly, in the present study, we report the synthesis of
compounds 1a-d, 2a-f, 12a-d, and 16a-f, along with their
COX (COX-1 and COX-2) inhibiting properties and their
rationalization through docking simulations. Compound 1d, with
the best biological profile in terms of affinity and selectivity
toward COX-2, as well as percent inhibition of the enzyme (cell
culture assay), was also investigated for its in vivo anti-
inflammatory and analgesic activity. Moreover, the selectivity
of this compound was also determined by the human whole
blood (HWB) in vitro assay, which assesses the pattern of
relative inhibition for human blood COX-1 and COX-2.
Chemistry
The synthesis of the target compounds is described in
Schemes 1 and 2. Briefly, the reaction of 4-methylthiobenzal-
dehyde with methyl vinyl ketone, according to the Stetter
conditions,18 was very versatile and high yielding in the
preparation of the 1,4-diketone 9, which was transformed into
the corresponding 4-methylsulfonyl derivative 10 by means of
oxone oxidation.19 Compound 10, heated in the presence of the
appropriate arylamine, according to the usual Paal-Knoor
(thermal) condensation, cyclized after a prolonged reflux to yield
the expected 3-unsubstituted 1,5-diarylpyrroles 11a-d in sat-
isfactory yield. The construction of the acetic acid chain was
achieved by regioselective acylation20 of 11a-d with ethoxalyl
chloride in the presence of pyridine to give derivatives 12a-d,
that were in turn reduced by means of triethylsilane in
trifluoroacetic acid21 to give pyrroleacetic esters 1a-d.
In a similar way, compounds 2a-f were prepared starting
from the appropriate benzaldehyde (13a-f), which was reacted
with methyl vinyl ketone, according to the Stetter conditions,
to give intermediates 14a-f. They were in turn heated in the
presence of 4-methylsulfonylaniline (obtained by H2O2 oxida-
tion22 of the corresponding 4-methylthioaniline), according to
the usual Paal-Knoor (thermal) condensation, to give, after a
prolonged reflux, the expected 3-unsubstituted 1,5-diarylpyrroles
15a-f in satisfactory yield. The construction of the acetic acid
side chain and its subsequent reduction were achieved following
the same method described above for compounds 1a-f, thus
leading to 16a-f and 2a-f, respectively.
Chart 1. Chemical Structure of Current Inhibitors of COX-2
Scheme 1a
a Compounds: 1a: R ) 4-F, 71% yield; 1b: R ) 3,4-F2, 60% yield; 1c: R ) 4-OMe, 30% yield; 1d: R ) 3-F, 30% yield; 11a: R ) 4-F; 11b: R )
3,4-F2; 11c: R ) 4-OMe; 11d: R ) 3-F; 12a: R ) 4-F, 82% yield; 12b: R ) 3,4-F2, 77% yield; 12c: R ) 4-OMe, 75% yield; 12d: R ) 3-F, 57% yield.
Reagents and conditions: (i) CH2dCHCOMe, NEt3, EtOH, 75-80 °C, 20 h, thiazolium; (ii) oxone, MeOH/H2O, rt, 2 h; (iii) RPhNH2, TiCl4, toluene, reflux,
10 h; (iv) EtOCOCOCl, pyridine, CH2Cl2, 0 °C, 4 h; (v) Et3SiH, CF3COOH, rt, 24 h.
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Biology
Compounds 1a-d, 2a-f, 12a-d, and 16a-f were all
evaluated for their anti-inflammatory activity toward both
COX-2 and COX-1 enzymes.
To evaluate COX-1 activity, cells were pretreated with a
reference standard (celecoxib) or the test compound (0.01-10
íM) for 15 min and further incubated at 37 °C for 30 min with
15 íM arachidonic acid in order to activate the constitutive
COX. At the end of the incubation, the supernatants were
collected for the measurement of prostaglandin E2 (PGE2) levels
by radioimmunoassay. On the other hand, to evaluate COX-2
activity, cells were stimulated for 24 h with E. coli lipopolysac-
charide (LPS, 10 íg/mL) to induce COX-2, in the absence or
presence of test compounds, at the concentrations previously
reported. The supernatants were collected for the measurement
of PGE2 by radioimmunoassay. Throughout the time the
experiments lasted, triplicate wells were used for the various
conditions of treatment. Results are expressed as the mean, for
three experiments, of the percent inhibition of PGE2 production
by test compounds with respect to control samples.
Compound 1d was also evaluated for COX-1 versus COX-2
selectivity by the use of the HWB assay. To evaluate COX-2
activity, 1 mL aliquots of peripheral venous blood samples were
incubated in the presence of LPS (10 íg/mL) or saline for 24
h at 37 °C, as previously described.23 As an index of LPS-
induced monocyte COX-2 activity, PGE2 plasma levels were
measured by RIA.23 COX-1 assay was performed on peripheral
venous blood samples drawn from the same donors when they
had not taken any NSAID during the two weeks preceding the
study. Whole blood TXB2 production was measured, by RIA,
as a reflection of maximally stimulated platelet COX-1 activity
in response to endogenously formed thrombin.24
Celecoxib and compound 1d were tested at the final
concentrations of 0.01-100 íM in both COX-2 and COX-1
assay.
Moreover, in vivo anti-inflammatory activity of 1d was also
assessed. Male Swiss albino mice (23-25 g) and Sprague-
Dawley or Wistar rats (150-200 g) were used. The animals
were fed with a standard laboratory diet and tap water ad libitum
and kept at 23 ( 1 °C, with a 12 h light/dark cycle, light on at
7 a.m. The paw pressure test was performed, inducing an
inflammatory process in the administering i.p. carrageenan 4 h
before the test. The carrageenan-induced paw edema test was
also performed, evaluating the paw volume of the right hind
paw 5 h after the injection of carrageenan and comparing it
with saline/carrageenan-treated controls. The analgesic activity
of 1d was also assessed by performing the abdominal constric-
tion test, using mice injected i.p. with a 0.6% solution of acetic
acid (10 mL/kg). The number of stretching movements was
counted for 10 min, starting 5 min after acetic acid injection.
Results and Discussion
Ester (1a-d and 2a-f) and R-ketoester (12a-d and 16a-f)
derivatives were synthesized to obtain new compounds more
active than 7a (Chart 1), previously described.17 Therefore, in
the attempt to determine the combined effects of positional,
steric, and electronic properties of the substituents on either
COX-1 and COX-2 inhibitory potency or COX isozyme
selectivity, different substituents were introduced at the pyrrole
N1 phenyl ring (such as 3-F, 4-F, 3,4-F2, and 4-OCH3), while
keeping unchanged the 4-SO2CH3 group at the C5 phenyl ring
(as in 1a-d and 12a-d). The corresponding regioisomers 2a-f
and 16a-f were also synthesized by introducing phenyl, 4-CH3-
phenyl, 4-CF3-phenyl, 4-F-phenyl, 3-F-phenyl, 3,4-F2-phenyl,
and 4-OCH3-phenyl substituents at the pyrrole C5 and maintain-
ing the 4-SO2CH3-phenyl substituent at N1.
Biological data and SAR analysis confirmed the dependence
of the activity on the nature and the mutual position of the
substituents on both the phenyl rings at C5 and N1 of the pyrrole
ring. In detail, according to our previous results,17 ester
derivatives 1a-d were more active toward COX-2 than the
corresponding R-ketoesters 12a-d (0.010 íM, 0.020 íM, 0.026
íM, and 0.010 íM versus 11 íM, 8.4 íM, 0.94 íM, and 0.90
íM, respectively, Table 1). Moreover, COX-1/COX-2 selectivity
was much higher than that found for compounds 12a-d.
Compounds 2a-c and 2e showed a micromolar activity toward
Scheme 2a
a Compounds. 2a: R ) 4-F, 65% yield; 2b: R ) 3,4-F2, 65% yield; 2c: R ) 4-OMe, 65% yield; 2d: R ) H, 65% yield; 2e: R ) 4-Me, 50% yield;
2f: R ) 4-CF3, 65% yield; 13a: R ) 4-F; 13b: R ) 3,4-F2; 13c: R ) 4-OMe; 13d: R ) H; 13e: R ) 4-Me; 13f: R ) 4-CF3; 14a: R ) 4-F; 14b: R
) 3,4-F2; 14c: R ) 4-OMe; 14d: R - H; 14e: R ) 4-Me; 14f: R ) 4-CF3; 15a: R ) 4-F; 15b: R ) 3,4-F2; 15c: R ) 4-OMe; 15d: R ) H; 15e: R )
4-Me; 15f: R ) 4-CF3; 16a: R ) 4-F, 75% yield; 16b: R ) 3,4-F2, 80% yield; 16c: R ) 4-OMe, 70% yield; 16d: R ) H, 72% yield; 16e: R ) 4-Me,
74% yield; 16f: R ) 4-CF3, 70% yield. Reagents and conditions: (i) CH2dCHCOMe, NEt3, EtOH, 75-80 °C, 20 h, thiazolium; (ii) H2O2/Na2WO4,
CH3COOH/H2O, rt, 1.5 h; (iii) p-MeO2SPhNH2, TiCl4, toluene, reflux, 10 h; (iv) EtOCOCOCl, pyridine, CH2Cl2, 0 °C, 4 h; (v) Et3SiH, CF3COOH,
rt, 24 h.
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COX-2, also retaining some COX-1/COX-2 selectivity. The
marked difference in activity among the ester derivatives
suggested the importance of the SO2Me pharmacophoric portion
in the phenyl ring when placed at C5 instead of N1. Furthermore,
compounds 1a-d showed inhibition values toward COX-2
(0.010, 0.020, 0.026, and 0.010 íM, respectively) higher than
that of celecoxib (0.06 íM) or the previously described lead
compound 7a (0.04 íM). Similarly, COX-1/COX-2 selectivity
was significantly improved in comparison to both 7a and the
reference compounds.
Analysis of the influence of substituents and substitution
pattern on the activity and selectivity toward COX-2 showed
that the presence and the position occupied by the fluorine atom
at the N1 phenyl ring plays an important role in defining the
inhibitory activity toward COX-2 in the in vitro cell culture
assay. In particular, 1d, bearing a fluorine atom at the meta
position, was found to be the most active compound (0.010 íM).
Moving the fluorine substituent to the para-position, as for 1a,
activity was maintained, while the simultaneous presence of two
fluorine atoms at the meta and para positions (1b) led to a slight
reduction of activity (0.020 íM) and selectivity. SAR data
indicate that the SO2Me at the C5 phenyl ring and a fluorine
substituent at the N1 phenyl ring are cooperative determinants
of both potent and selective COX-2 inhibition.
Compound 1d was submitted to further pharmacological tests.
In particular, the HWB assay was performed to predict the actual
extent of isozyme inhibition achievable in vivo by circulating
drug levels, because of a number of variables potentially
affecting drug-enzyme interaction. Results indicated that, in
these experimental conditions, the situation is reversed with
celecoxib being more selective than compound 1d. In fact,
celecoxib showed a COX-1/COX-2 IC50 ratio of 23 in the HWB
assay (Figure 1), whereas a COX-1/COX-2 IC50 ratio of 62 was
found in cell culture assay. On the other hand, 1d showed a 9.7
ratio in the HWB assay and a >10 000 ratio in cell culture assay.
The discrepancy of these results could be due to different
inhibitor sensitivities shown by the mouse and human COX
isozymes, as reported for other anti-inflammatory compounds.23
Finally, to assess in vivo anti-inflammatory and analgesic
activity of 1d, the rat paw pressure test, the paw volume test,
and the abdominal constriction test were also performed (Tables
2-4). This compound, administered at a dose of 20 mg/kg p.o.,
showed a very good activity against carrageenan-induced
hyperalgesia 30 min after administration. Such an analgesic
activity at this time was very similar to that obtained with
celecoxib (10 mg/kg p.o.). However, in contrast to what was
observed with this standard compound, the activity tended to
fade at longer time-points (1 h), disappearing almost completely
2 h after administration (Table 2). In parallel, a very good
Table 1. In Vitro Inhibition (J774 Murine Macrophage Assay) of
COX-1 and COX-2 by Compounds 1a-d, 2a-f, 12a-d, 16a-f and
Celecoxib
IC50a
(íM)
COX-2 inhibition
(%)
cmpd COX-1 COX-2 10 íM 1 íM selectivity indexb
1a >100 0.010 100 100 >10 000
1b >100 0.020 100 87 >5000
1c >100 0.026 90 87 >4000
1d >100 0.010 100 91 >10 000
2a >100 0.40 75 50 >250
2b >100 5.40 62 35 >19
2c >100 0.55 78 59 >200
2d >100 NDc 27 0
2e >100 1.96 79 33 >50
2f >100 ND ND ND
12a >100 11.0 51 19 >9
12b >100 8.40 55 8 >12
12c >100 0.94 70 59 >100
12d >100 0.90 75 55 >100
16a >100 ND 12 0
16b >100 ND 29 0
16c >100 ND 49 21
16d >100 ND 30 0
16e >100 ND 25 0
16f >100 ND 34 30
celecoxib 3.7 0.06 100 80 61.7
a Results are expressed as the mean (n ) 3) of the % inhibition of PGE2
production by test compounds with respect to control samples. b In vitro
COX-2 selectivity index (IC50(COX-1)/IC50(COX-2)). c ND: not determined.
Figure 1. In vitro inhibition (whole blood assay) of COX-1 and COX-2
by celecoxib (A) and 1d (B). Results are expressed as average percent
inhibition of three donors of prostanoid production assessed in the
absence of the test compounds (control). COX-2 selectivity index
(IC50(COX-1)/IC50(COX-2)).
Figure 2. Graphical representation of the binding mode of 1b (black)
with respect to the cocrystallized inhibitor SC-558 (green, ball and stick
notation). Portions of the binding site are labeled according to the
notation of Kurumbail and co-workers.26
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activity was demonstrated against carrageenan-induced oedema
in the rat paw (Table 3), with a complete remission 1 h after
the administration (20 mg/kg p.o.). Moreover, a dose-dependent
anti-nociceptive activity was observed in the abdominal con-
striction test (Table 4).
Molecular Modeling Simulations
In a previous work,17 a series of 1,5-diarylpyrrole derivatives
was submitted to a two-step computational protocol consisting
of molecular docking calculations and structural optimization
of the complexes obtained, with the aim of investigating on the
possible interaction mode of such inhibitors within the COX-2
binding site. Moreover, Grid maps25 were calculated for some
probe atoms or groups to evaluate the regions of best interaction
between the inhibitors and the macromolecule. As a result, in
addition to findind for the inhibitors an orientation very similar
to that of the cocrystallized ligand SC-558, molecular modeling
simulations suggested structural modifications of the parent
compounds to synthesize a second generation of pyrrole
derivatives endowed with an improved biological profile. In
particular, the analysis of the Grid map generated for the fluoride
probe suggested that a fluorine substituent at the para positions
of the pyrrole N1-phenyl ring (similar to the bromine atom of
SC-558) and, additionally, at the meta position of the same ring,
could improve the interaction with the COX-2 binding site,
involving Trp387, Tyr348, and Tyr385 of the hydrophobic
cavity. Accordingly, the three fluorinated derivatives 1a, 1b,
and 1d were found to have a very low IC50 toward COX-2 (up
to a 10 nM concentration) with a selectivity index (expressed
as the ratio between IC50(COX-1)/IC50(COX-2)) higher than 10 000,
further validating the reliability of the computational protocol
in finding the binding mode of 1,5-diaryl-2-methyl-3-substituted
pyrrole derivatives within the COX-2 binding site.
The new derivatives were submitted to the same computa-
tional protocol previously reported, with the aim of analyzing
their interactions with amino acids of the COX-2 binding site.
In the complexes obtained, the diaryl system of compounds 1
was superposed on the corresponding structural feature of the
cocrystallized inhibitor. In particular, the difluorophenyl ring
at N1 of the pyrrole core of 1b and the p-bromophenyl moiety
of SC-558 were located in the hydrophobic pocket (according
to the notation used by Kurumbail et al.)26 and interacted with
the side chains of hydrophobic (Leu384) and aromatic (Tyr385,
Trp387, and Phe518) residues (Figure 2). As expected, fluorine
substituents at the meta and para positions of the N1 phenyl
ring lay on one of the best interaction regions of the fluoride
Grid map. Moreover, the methyl group at the position 2 of the
pyrrole ring provided profitable interactions with the hydro-
phobic side chains of Val349 and Ala527. This result was in
agreement with the Grid map generated for the methyl probe,
showing a profitable interaction point (at -3.0 kcal/mol)
corresponding to the region occupied by the 2-methyl group of
inhibitors, also in agreement with previous findings suggesting
that such a substituent at this position leads to the optimal
potency.19 On the other hand, the ester moiety at position 3 of
1b was superposed on the trifluoromethyl group of the cocrys-
tallized inhibitor and was involved with its oxygen atoms in
hydrogen bond contacts with the basic terminal group of the
Arg120 side chain (belonging to the classical NSAID’s car-
boxylate binding site), in agreement with the carbonyl Grid map
showing that the Arg120 side chain was surrounded by regions
of profitable interactions with a carbonyl group (at -7 kcal/
mol), including the position occupied by the carbonyl ester group
of 1b. The alkyl portion of the ester group interacted with
Val116 and Tyr355 and was directed toward the solvent
accessible surface. Finally, the p-methylsulfonylphenyl moiety
at the position 5 of 1b occupied the same region of space as
the p-sulfonamidophenyl substituent of SC-558, both of them
being accommodated within the selectivity site. In this context,
the entire p-methylsulfonylphenyl group of the inhibitor was
involved in profitable interactions with COX-2 residues. In fact,
the oxygen atoms of the sulfone groups showed hydrogen bond
contacts with the terminal NH2 group of Gln192 and with the
backbone NH group of Phe518, while the aromatic ring
interacted with the side chain of hydrophobic amino acids, such
as Leu352 and Val523.
Inversion of the substitution pattern at positions 1 and 5 of
the pyrrole ring of compounds 1 led to 2, characterized by a
marked decrease in activity toward COX-2 (up to 270-fold,
compare 1b vs 2b), accounted for by a different interaction
pathway with the enzyme, due to a reorientation of the inhibitors
within the binding site. As an example, the first-ranked
orientation of 2b, while characterized by the usual orientation
of the fluorophenyl moiety within the hydrophobic pocket,
Table 2. Effect of Compound 1d in the Rat Paw-Pressure Test, in Comparison to Celecoxiba
paw pressure (g)
after treatment
pretreatment treatment
before
pretreatment
30
min
60
min
120
min
saline saline 62.0 ( 4.3 62.6 ( 5.2 63.5 ( 4.6 64.2 ( 5.2
carrageenan saline 61.9 ( 5.1 38.7 ( 5.3 35.8 ( 4.5 40.1 ( 5.0
carrageenan 1d 61.7 ( 3.9 55.2 ( 3.6 49.8 ( 4.1 43.4 ( 4.9
carrageenan celecoxib 62.7 ( 3.9 56.5 ( 3.8 58.2 ( 4.4 55.2 ( 5.1
a Compound 1d and celecoxib were administered, respectively, at the dose of 20 and 10 mg/kg.
Table 3. Effect of Compound 1d in Comparison with Celecoxib in the
Edema Induced by Carrageenana
paw volume (mL)
pretreatment treatment
before
pre-
treatment
60 min
after
treatment
% of
paw-edema
suppression
saline saline 1.26 ( 0.09 1.31 ( 0.10
carrageenan saline 1.22 ( 0.08 2.33 ( 0.08
carrageenan 1d 1.24 ( 0.11 1.29 ( 0.14 95.5
carrageenan celecoxib 1.28 ( 0.14 1.33 ( 0.10 95.5
a Compound 1d and celecoxib were administered, respectively, at the
dose of 20 and 10 mg/kg.
Table 4. Effect of Compound 1d in the Mouse Abdominal Constriction
Test (0.6% Acetic Acid)
treatmenta
number of
mice
dose
(p.o. mgâkg-1)
number of
writhes
CMC 20 31.4 ( 4.3
1d 10 10 28.9 ( 23.9
1d 7 20 15.7 ( 3.6
a All compounds were administered per os 30 min before test. *P <
0.01 versus vehicle-treated mice.
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showed the ester side chain anchored to the selectivity site by
a hydrogen bond between the carbonyl oxygen and the NH
group of Phe518 and by hydrophobic contacts involving the
ethyl terminal group and a portion of the Gln192 side chain.
On the other hand, the methyl group at the position 2 of the
pyrrole ring was accommodated into a region defined by His90,
Ser353, and Tyr355 without any profitable interaction, while
the aromatic moiety at N1 was embedded into the carboxylate
site. In particular, one of the sulfone oxygens interacted by a
hydrogen bond the guanidino group of Arg120, and the terminal
methyl group linked to the sulfur atom was allocated to a large
hydrophobic region delimited by the side chains of Val116,
Leu359, and Lue531. Although the best orientation of 2b
showed electrostatic and hydrophobic interactions contributing
to the stabilization of the complex with COX-2, it lacked
additional contacts found for 1b, thus accounting for the marked
decreased activity of 2b with respect to 1b. As examples,
hydrogen bonds at both the carboxylate site (namely, with
Arg120) and the selectivity site (namely, with Gln192) were
omitted, as well as the hydrophobic interactions involving the
2-methyl group. Inspection of the various orientations/confor-
mations found for 2b during docking simulations led us to
identify an orientation of the inhibitor, very similar to that of
the best ranked orientation of 1b. In fact, while substituents at
positions 1, 3, and 5 of 2b were isooriented with respect to the
same substituents of 1b (i.e., the methylsulfonylphenyl group
into the selectivity site, the fluorophenyl moiety into the
hydrophobic pocket, and the ester side chain into the carboxylate
site), the methyl group at position 2 of 2b pointed toward Tyr355
and, to avoid steric clashes with this residue, caused a translation
of the molecule toward the hydrophobic pocket with a conse-
quent lack of hydrogen bond contacts with Arg120. In summary,
docking calculations showed that the most frequent orientations
of 2b within the binding site were all characterized by interaction
pathways accounting for the lower activity of this compound
with respect to the corresponding isomer 1b.
Regarding keto-ester derivatives, the conformational rigidity
introduced at the position 3 significantly influenced their binding
mode into the binding site of COX-2. As an example, the best
orientation of 12b showed the methylsulfone group accom-
modated within the hydrophobic pocket, while the methyl group
was in the carboxylate site. In such an orientation, although
the ester carbonyl group of the inhibitor made the usual
hydrogen bond with the NH of Phe518, the remaining interac-
tions (i.e., the hydrogen bond involving Arg120 and the ester
chain and the contacts with the hydrophobic pocket), important
for a profitable binding within the active site, were lost.
Considering the low affinity with respect to the corresponding
ester derivatives (and consequent lower selectivity between the
two forms of the enzyme), probably due to the different
structural properties introduced into the side chain at the position
3 of the pyrrole nucleus, keto-esters were not considered
attractive compounds and were not investigated further.
Conclusions
Based on suggestions derived from both SAR analysis and
molecular modeling simulations on 1,5-diarylpyrrole derivatives,
a new series of compounds has been designed and synthesized.
Biological data showed a significant enhancement of their
affinity toward COX-2 and an improvement of COX-2/COX-1
selectivity, with respect to the parent compounds in the in vitro
cell culture assay.
One of the new entries (namely, 1d) was selected for further
in vitro and in vivo experiments. In the HWB assays, 1d had a
COX-1/COX-2 ratio lower than that of the reference drug
celecoxib, but comparable to that of other NSAIDs, such as
meloxicam.27 The new compound showed a very interesting
anti-inflammatory and analgesic activity, laying the foundations
for developing new lead compounds that could be effective
agents in the management of inflammation and pain.
Experimental Section
Chemistry. All chemicals used were of reagent grade. Yields
refer to purified products and are not optimized. Melting points
were determined in open capillaries on a Gallenkamp apparatus
and are uncorrected. Microanalyses were carried out by means of
a Perkin-Elmer 240C or a Perkin-Elmer Series II CHNS/O Analyzer
2400. Merck silica gel 60 (230-400 mesh) was used for column
chromatography. Merck TLC plates, silica gel 60 F254 were used
for TLC. 1H NMR spectra were recorded with a Bruker AC 200
spectrometer in the indicated solvent (TMS as internal standard).
The values of the chemical shifts are expressed in ppm and the
coupling constants (J) in Hz. Mass spectra were recorded on either
a Varian Saturn 3 or a ThermoFinnigan LCQ-deca spectrometer.
General Procedure for Preparation of Pentane-1,4-diones 9
and 14a-f. To a solution of the suitable benzaldehyde (12 mL,
0.09 mol) in ethanol (30 mL), triethylamine (19.5 mL, 0.14 mol),
methyl vinyl ketone (5.8 mL, 0.07 mol), and 3-ethyl-5-(2-
hydroxyethyl)-4-methylthiazolium bromide (3.53 g, 0.014 mol) were
added. The mixture was heated at 75-80 °C for 20 h under nitrogen
and then cooled. The solvent was removed under reduced pressure
and the residue treated with 2 N HCl (300 mL). After extraction
with dichloromethane, the organic layer was washed with aqueous
NaHCO3 and water. The organic fractions were dried over Na2-
SO4, filtered, and concentrated to give a crude orange liquid (16.2
g). After chromatography on silica gel (hexane/ethyl acetate, 7/3
v/v), the desired compounds 9 or 14a-f were isolated (yield 70%)
as a light yellow solid which, after recrystallization from hexane,
gave an analytical sample as light yellow needles.
Examples. 1-[4-(Methylthio)phenyl]pentane-1,4-dione (9). Yel-
lowish needles (yield 78%). Analytical data, mp, and 1H NMR
spectrum were consistent with those reported in the literature.19
1-[4-(3,4-Difluoro)phenyl]pentane-1,4-dione (14b). Yellowish
needles (yield 78%), mp 57 °C; 1H NMR (CDCl3) 7.77 (m, 2H),
7.23 (m, 1H), 3.18 (t, J ) 6.7 Hz, 2H), 2.88 (t, J ) 6.7 Hz, 2H),
2.23 (s, 3H). Anal. (C11H10O2F2) C, H, O, F.
1-[4-(Methoxy)phenyl]pentane-1,4-dione (14c). Yellowish
needles (yield 77%). Analytical data, mp, and 1H NMR spectrum
were consistent with those reported in the literature.28
1-[4-(Methylsulfonyl)phenyl]pentane-1,4-dione (10). To a so-
lution of 9 (7.8 g, 35 mmol) in methanol (150 mL), oxone (37.7 g,
61.4 mmol), dissolved in water (150 mL), was added over 5 min.
After stirring at 25 °C for 2 h, the reaction mixture was diluted
with water (400 mL) and extracted with dichlorometane (3  400
mL). The organic layer was washed with brine (200 mL) and water
(200 mL) and dried (Na2SO4). After filtration and concentration,
the crude material was chromatographed (silica gel, hexane/ethyl
acetate, 3/1) to give 10 (yield 90%) as a yellowish solid that, after
recrystallization from hexane/ethyl acetate, gave an analytical
sample as white needles. Analytical data, mp, and 1H NMR
spectrum were consistent with those reported in the literature.19
4-Methylsulfonylaniline. A mixture of Na2WO4 (0.067 g), 8
drops of acetic acid, and H2O (19 mL) was placed in a flask and
heated to 65 °C. 4-Methylthioaniline (19 mL, 153 mmol) was added,
followed by dropwise addition of H2O2 (34.5 mL, 337 mmol). The
mixture was stirred at 65 °C for 1.5 h and, after cooling, 800 mL
of 1 N HCl and 500 mL of CHCl3 were added. The layers were
separated, and the aqueous phase was washed with additional
CHCl3. The aqueous phase was basified with 25% NaOH and
extracted with CHCl3. The organic phase was washed with brine
and dried over Na2SO4. The solvent was removed to give 4-
methylsulfonylaniline as a white solid. Analytical data, mp, and
1H NMR spectrum were consistent with those reported in the
literature.22
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General Procedure for the Preparation of 1,5-Diarylpyrroles
11a-d and 15a-f. These compounds were prepared by means of
the Paal-Knorr reaction by condensing a 1,4-diketone with the
appropriate aniline. Briefly, a mixture of diketone 10 or 14a-f (2.28
mmol) and the suitable aniline (2.5 mmol) in the presence of
p-toluenesulfonic acid (30 mg) in dry toluene (50 mL) was refluxed
for 20 h using a Dean-Stark apparatus. The reaction mixture was
cooled, filtered, and concentrated. The crude material was purified
by flash chromatography with a hexane/ethyl acetate (7/3 v/v)
mixture as the eluent to give the expected 1,5-diarylpyrrole as a
solid in satisfactory yield. Recrystallization from hexane/ethyl
acetate gave the required product.
2-Methyl-5-[4-(methylsulfonyl)phenyl]-1-[4-(methoxy)phenyl]-
1H-pyrrole (11c). White needles (yield 85%), mp 144 °C, 1H NMR
(CDCl3) 7.67 (d, 2H, J ) 7.27 Hz), 7.19 (d, 2H, J ) 7.27 Hz),
7.07 (d, 2H, J ) 7.27 Hz), 6.92 (d, 2H, J ) 7.27 Hz), 6.50 (d, 1H,
J ) 3.5 Hz), 6.11 (d, 1H, J ) 3.5 Hz), 3.84 (s, 3H), 3.00 (s, 3H),
2.12 (s, 3H). Anal. (C19H19NO3S) C, H, N, O, S.
2-Methyl-1-[4-(methylsulfonyl)phenyl]-5-[4-(methoxy)phenyl]-
1H-pyrrole (15c). Yellowish needles (yield 82%), mp 156 °C, 1H
NMR (CDCl3) 7.93 (d, 2H, J ) 7.27 Hz), 7.30 (d, 2H, J ) 7.27
Hz), 6.93 (d, 2H, J ) 7.27 Hz), 6.92 (d, 2H, J ) 7.27 Hz), 6.27 (d,
1H, J ) 3.5 Hz), 6.11 (d, 1H, J ) 3.5 Hz), 3.75 (s, 3H), 3.09 (s,
3H), 2.17 (s, 3H). Anal. (C19H19NO3S) C, H, N, O, S.
General Procedure for the Preparation of Ethyl 1,5-Dia-
rylpyrrol-3-ylglyoxylic Esters 12a-d or 16a-f. These compounds
were prepared by reaction of ethoxalyl chloride with the appropriate
pyrrole in the presence of pyridine, as previously reported.20 A
solution of pyridine (11 mmol) in anhydrous dichloromethane was
added to a strirred solution of ethoxalyl chloride (1.22 mL, 10
mmol) in dichloromethane (15 mL) at a rate that allowed the
temperature to be maintained between -20 to -25 °C. Immediately
after, a solution of the pyrrole derivative (10 mmol) in dichlo-
romethane (15 mL) at the same temperature was added. The solution
was stirred for 4 h at 0 °C, then washed in sequence with dilute
HCl and saturated aqueous NaCl solution. The organic solution
was dried and evaporated in vacuo. Purification of the residue by
flash chromatography with ethyl acetate as the eluant gave a solid
which, after recrystallization from hexane/ethyl acetate, afforded
the expected product.
Ethyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1-[4-(fluoro)-
phenyl]-1H-pyrrol-3-glyoxylate (12a). Yellowish needles (yield
82%), mp 146 °C, 1H NMR (CDCl3) 7.93 (m, 2H), 7.76 (m, 2H),
7.00 (m, 2H), 7.02 (m, 2H), 6.00 (s, 1H), 4.20 (q, 2H, J ) 7.1 Hz),
2.86 (s, 3H), 2.16 (s, 3H), 1.30 (t, 3H, J ) 7.1 Hz). Anal. (C22H20-
NO5SF) C, H, N, S, O, F.
Ethyl-2-methyl-1-[4-(methylsulfonyl)phenyl]-5-[4-(fluoro)-
phenyl]-1H-pyrrol-3-glyoxylate (16a). Yellowish needles (yield
75%), mp 187 °C, 1H NMR (CDCl3) 7.90 (m, 2H), 7.50 (m, 2H),
7.46 (m, 2H), 7.03 (m, 2H), 6.00 (s, 1H), 4.20 (q, 2H, J ) 7.1 Hz),
2.86 (s, 3H), 2.16 (s, 3H), 1.30 (t, 3H, J ) 7.1 Hz). Anal. (C22H20-
NO5S) C, H, N, S, O, F.
1,5-Diarylpyrrole-3-acetic Esters 1a-d or 2a-f. These com-
pounds were prepared by reduction of the appropriate glyoxylic
derivative by means of triethylsilane in TFA21 under a nitrogen
atmosphere at 0 °C. To a solution of the suitable R-keto ester (2.3
mmol) in TFA (9 mL) stirred at 0 °C under nitrogen, triethylsilane
(0.75 mL, 4.7 mmol) was slowly added, and the mixture was stirred
for 30 min at rt. At the end of the reaction, the mixture was made
alkaline with 40% aqueous ammonia (10 mL) and extracted with
CHCl3 (250 mL). The organic solution was dried and evaporated
in vacuo. The resulting residue was chromatographed on silica gel
eluting with CHCl3 to give a solid which, after recrystallization
from hexane/ethyl acetate, afforded the desired product.
Ethyl-2-methyl-5-[4-(methylsulfonyl)phenyl]-1-[4-(fluoro)-
phenyl]-1H-pyrrol-3-acetate (1a). Yellowish needles (yield 71%),
mp 133 °C, 1H NMR (CDCl3) 7.99 (m, 2H), 7.76 (m, 2H), 7.20
(m, 2H), 7.00 (m, 2H), 5.80 (s, 1H), 4.12 (q, 2H, J ) 7.1 Hz), 3.39
(s, 2H), 2.84 (s, 3H), 2.16 (s, 3H), 1.30 (t, 3H, J ) 7.1 Hz). Anal.
(C22H22NO4SF) C, H, N, S, O, F.
Ethyl-2-Methyl-1-[4-(methylsulfonyl)phenyl]-5-[4-(fluoro)-
phenyl]-1H-pyrrol-3-acetate (2a). Yellowish needles (yield 65%),
mp 144 °C, 1H NMR (CDCl3) 7.92 (m, 2H), 7.50 (m, 2H), 7.46
(m, 2H), 7.03 (m, 2H), 5.80 (s, 1H), 4.12 (q, 2H, J ) 7.1 Hz), 3.39
(s, 2H), 2.82 (s, 3H), 2.12 (s, 3H), 1.33 (t, 3H, J ) 7.1 Hz). Anal.
(C22H22NO4SF) C, H, N, S, O, F.
Biology. Arachidonic acid was obtained from SPIBIO (Paris,
France). [3H]-PGE2 and [3H]-TXB2 were from Perkin-Elmer Life
Sciences (Milan, Italy). All other reagents and compounds used
were obtained from Sigma-Aldrich (Milan, Italy).
Cellular Assay. Cell Culture. The murine monocyte/macroph-
age J774 cell line was grown in Dulbecco’s modified Eagles
medium (DMEM) supplemented with 2 mM glutamine, 25 mM
Hepes, penicillin (100 U/mL), streptomycin (100 íg/mL), 10%
foetal bovine serum (FBS), and 1.2% sodium pyruvate (Bio
Whittaker, Europe). Cells were plated in 24-well culture plates at
a density of 2.5  105 cells/mL or in 10 cm-diameter culture dishes
(1  107 cells/10 mL/dish) and allowed to adhere at 37 °C in 5%
CO2/95% O2 for 2 h. Immediately before the experiments, the
culture medium was replaced by a fresh medium without FBS to
avoid interference with radioimmunoassay,29 and cells were stimu-
lated as described.
Assessment of COX-1 Activity. Cells were pretreated with the
reference standard or the test compounds (0.01-10 íM) for 15
min and further incubated at 37 °C for 30 min with 15 íM
arachidonic acid to activate the constitutive COX.28 Stock solutions
of the reference standard or of the test compounds were prepared
in dimethyl sulfoxide (DMSO), and an equivalent amount of DMSO
was included in control samples. At the end of the incubation, the
supernatants were collected for the measurement of PGE2 by
radioimmunoassay.
Assessment of COX-2 Activity. Cells were stimulated for 24 h
with E. coli lipopolysaccharide (LPS, 10 íg/mL) to induce COX-
2, in the absence or presence of test compounds, at the concentra-
tions previously reported. The supernatants were collected for the
measurement of PGE2 by radioimmunoassay.
Human Whole Blood (HWB) Assay. Subjects. Three healthy
volunteers (2 females and 1 male, aged 29 ( 3 years) were enrolled
to participate in the study after its approval by the Ethical
Committee of the University of Chieti. Informed consent was
obtained from each subject.
COX-2 Assay. To evaluate COX-2 activity, 1 mL aliquots of
peripheral venous blood samples containing 10 i.u. of sodium
heparin were incubated in the presence of LPS (10 íg/mL) or saline
for 24 h at 37 °C, as previously described.23 The contribution of
platelet COX-1 was suppressed by pretreating the subjects with
aspirin (300 mg, 48 h) before sampling. Plasma was separated by
centrifugation (10 min at 2000 rpm) and kept at -80 °C until
assayed for PGE2, as an index of LPS-induced monocyte COX-2
activity.
COX-1 Assay. Peripheral venous blood samples were drawn
from the same donors when they had not taken any NSAID during
the 2 weeks preceding the study. Aliquots (1 mL) of whole blood
were immediately transferred into glass tubes and allowed to clot
at 37 °C for 1 h. Serum was separated by centrifugation (10 min at
3000 rpm) and kept at -80 °C until assayed for TXB2. Whole blood
TXB2 production was measured as a reflection of maximally
stimulated platelet COX-1 activity in response to endogenously
formed thrombin.24
Effects of COX-2 Inhibitors on Whole Blood COX-2 and
COX-1 Activities. Celecoxib (0.005-50 mM) and 1d (0.5-50
mM) were dissolved in DMSO. Aliquots of the solutions (2 íL)
were pipetted directly into test tubes to give final concentrations
of 0.01-100 íM in heparinized whole blood samples in the
presence of LPS (10 íg/mL) for 24 h or with whole blood samples
allowed to clot at 37 °C for 1 h to examine the concentration-
dependence of COX-2 versus COX-1 inhibition, respectively.
Analysis of PGE2 and TXB2. PGE2 and TXB2 concentrations
were measured by previously described and validated radioimmu-
noassays.23,24 Unextracted plasma and serum samples were diluted
in the standard diluent of the assay (0.02 M phosphate buffer, pH
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7.4) and assayed in a volume of 1.5 mL at a final dilution of 1:50-
1:30 000. [3H]PGE2 or [3H]TXB2 (4000 dpm, specific activity >
100 Ci/mmol, 1:100 000 dilution) and anti-TXB2 (1:120 000
dilution) sera were used. The least detectable concentration was
1-2 pg/mL for both prostanoids.
Statistical Analysis. Results are expressed as the mean, for three
experiments (triplicate wells were used for the various conditions
of treatment, in the cell culture assay) of the percent inhibition of
prostanoid production assessed in the absence of the test compounds
(control). Concentration-response curves were fitted, and IC50
values were analyzed with PRISM (GraphPad, San Diego, CA) and
ALLFIT, a basic computer program for simultaneous curve-fitting
based on a four-parameter logistic equation.
In Vivo Anti-Inflammatory Activity. Animals. Male Swiss
albino mice (23-25 g) and Sprague-Dawley or Wistar rats (150-
200 g) were used. Fifteen mice and four rats were housed per cage.
The cages were placed in the experimental room 24 h before the
test for acclimatization. The animals were fed in a standard
laboratory diet and tap water ad libitum and kept at 23 ( 1 °C
with a 12 h light/dark cycle, light on at 7 a.m. All experiments
were carried out in accordance with the NIH Guide for the Care
and Use of Laboratory animals. All efforts were made to minimize
animal suffering, and to reduce the number of animals used.
Paw Pressure Test. The nociceptive threshold in the rat was
determined with an analgesimeter, according to the method
described by Leighton.30 Threshold pressure was measured before
and 30, 60, and 120 min after treatment. An arbitrary cutoff value
of 250 g was adopted. To induce an inflammatory process in the
rat, paw carrageenan (0.1 mL, 1%) was administered i.pl. 4 h before
test.
Carrageenan-Induced Paw Edema. Rat paw volumes were
measured using a plethysmometer. Five hours after the injection
of carrageenan (0.1 mL injection of 1.0%) the paw volume of the
right hind paw was measured and compared with saline/carrag-
eenan-treated controls.31 Rats received test compounds 4 h after
carrageenan. Results are reported as paw volume expressed in mL.
Abdominal Constriction Test. Mice were injected i.p. with a
0.6% solution of acetic acid (10 mL/kg), according to Koster.32
The number of stretching movements was counted for 10 min,
starting 5 min after acetic acid injection.
Computational Details. All calculations and graphical manipu-
lations were performed on Silicon Graphics computers (Origin 300
server and Octane workstations) using the software package
Autodock 3.0.533 and MacroModel 8.5.34
Atomic coordinates of COX-2 used during molecular modeling
simulations were derived from the structure of the complex between
COX-2 and SC-558 (3a, Chart 1), refined at a 3 Å resolution
(Brookhaven Protein Data Bank entry: 6cox). To set the initial
coordinates for the docking studies, the residues belonging to chain
B and three N-acetyl-D-glucosamine residues present in chain A of
the crystal structure of COX-2 were removed and excluded from
all calculations.
The program Autodock was used to evaluate the binding mode
of the new inhibitors and to explore their binding conformations
within the COX-2 structure. A grid point spacing of 0.28 Å and 87
 81  97 points were used. The grid was centered on the mass
center of the crystallographic inhibitor. Parameters for docking runs
were set as follows (imported from a docking parameter file): outlev
1, diagnostic output level; rmstol 0.5, cluster_tolerance/A; extnrg
1000.0, external grid energy; e0max 0.0 10000, max initial energy;
max number of retries; ga_pop_size 50, number of individuals in
population; ga_num_evals 250000, maximum number of energy
evaluations; ga_num_generations 27000, maximum number of
generations; ga_elitism 1, number of top individuals to survive to
next generation; ga_mutation_rate 0.02, rate of gene mutation;
ga_crossover_rate 0.8, rate of crossover; ga_window_size 10;
ga_cauchy_alpha 0.0, Alpha parameter of Cauchy distribution;
ga_cauchy_beta 1.0, Beta parameter Cauchy distribution; set_ga,
set the above parameters for GA or LGA; sw_max_its 300,
iterations of Solis & Wets local search; sw_max_succ 4, consecutive
successes before changing rho; sw_max_fail 4, consecutive failures
before changing rho; sw_rho 1.0, size of local search space to
sample; sw_lb_rho 0.01, lower bound on rho; ls_search_freq 0.06,
probability of performing local search on individual; set_psw1, set
the above pseudo-Solis & Wets parameters; ga_run 100, do this
many hybrid GA-LS runs; analysis, perform a ranked cluster
analysis.
Based on the fact that Autodock does not perform any structural
optimization and energy minimization of the complexes found, a
molecular mechanics/energy minimization (MM/EM) approach was
applied to refine the Autodock output. The computational protocol
applied consisted in the application of 10 000 steps of the steepest
descent algorithm or until the derivative convergence was 0.01 kcal/
Åâmol. Moreover, because of the large number of atoms in the
model, to correctly optimize the COX-2-inhibitor complexes
obtained by the flexible docking, the following additional constraints
had to be imposed: (i) a subset, comprising only of the inhibitor
and a shell of residues possessing at least one atom at a distance
of 5 Å from any of the inhibitor atoms, was created and subjected
to energy minimization. The inhibitor and all the amino acid side
chains of the shell were unconstrained during energy minimization
to allow for reorientation and proper hydrogen-bonding geometries
and van der Waals contacts; (ii) all the atoms not included in the
above-defined subset were fixed, but their nonbond interactions with
all the relaxing atoms were calculated. Further details on this
computational protocol have been reported elsewhere.17
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